Financière de Tubize Expands Leadership in Biopharma Sector
In recent developments, Financière de Tubize is reinforcing its dedication to excellence in the biopharmaceutical sector. This move comes after the appointment of Bruno Holthof as Chairman of the Board of Directors. Under his leadership, the company seeks to enhance its contributions to a vibrant biopharmaceutical landscape, aligning closely with the needs of UCB.
New Appointments Bolster Board Expertise
The Extraordinary General Meeting recently confirmed the addition of two significant leaders to the board: Iris Löw-Friedrich and Carinne Brouillon. Both directors bring extensive international experience and a profound understanding of the biopharmaceutical industry.
Insights from the Chairman
Bruno Holthof expressed enthusiasm about these new appointments, stating, "With the arrival of Iris and Carinne, the level of biopharma expertise on our board will significantly increase. This enhancement is crucial during a pivotal period in UCB's evolution, allowing for more impactful participation in strategic discussions."
Cyril Janssen Takes on New Role
In alignment with its mission to uphold high standards of governance, the board has also appointed Cyril Janssen as Vice-President. His role will involve fostering strong relationships with family shareholders and collaborating closely with the Chairman to ensure effective governance practices.
Meet the New Directors
Iris Löw-Friedrich holds an MD and PhD, is board-certified in internal medicine, and has a wealth of experience in drug development. She has previously served as Head of Development and Chief Medical Officer at UCB and is currently a member of several boards, including Fresenius SE and Evotec SE.
Carinne Brouillon comes with a Doctor of Pharmacy degree from the University of Lyon, France, and boasts over 30 years of extensive experience in various roles within the healthcare industry. Her noteworthy tenure includes 21 years at Johnson & Johnson, and she has also held pivotal management positions at Boehringer Ingelheim and Munich Re.
Cyril Janssen’s Commitment
Janssen has publicly acknowledged the trust placed in him by the board, stating, "I am honored to receive the board's trust for this new role and I look forward to increasing my involvement within our board." His insights and leadership are anticipated to drive the company's strategic initiatives forward.
Frequently Asked Questions
What is the significance of the new appointments at Financière de Tubize?
The appointments of Iris Löw-Friedrich and Carinne Brouillon enhance the board's biopharmaceutical expertise, crucial for strategic discussions as the company navigates critical phases in its collaboration with UCB.
Who are the newly appointed directors?
Iris Löw-Friedrich, an experienced medical professional, and Carinne Brouillon, a seasoned leader in the pharmaceutical industry, have been appointed to the board, bringing valuable insights and skills?
What role will Cyril Janssen play in the company?
Cyril Janssen will serve as Vice-President, focusing on governance practices and maintaining relationships with family shareholders, bolstering the company's leadership structure.
How does Financière de Tubize aim to impact the biopharma sector?
The company aims to contribute meaningfully to a sustainable biopharma ecosystem by leveraging its board’s expertise and fostering collaborations within the industry.
What is the vision for the future of Financière de Tubize?
With enhanced leadership and strategic appointments, Financière de Tubize aims to elevate its influence in the biopharma sector while ensuring robust governance and innovative drug development.
